Share on LinkedInShare on LinkedIn

ARTICLE · 17 MAY 2023

The Future Of AI In The Pharmaceutical Industry

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases...

GlobalIntellectual Property

Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases, improving diagnostic speed and accuracy, accelerating drug discovery, and improving clinical trials.

AI's rapid growth makes it more important than ever for companies to safeguard their intellectual property.

AI as a diagnostic tool

AI is a powerful diagnostic tool. It can quickly analyze real-world data and detect subtle changes and patterns that humans may miss. In one study, researchers are testing whether AI can analyse MRI data to predict cancer patient outcomes better than well-trained radiologists. Similarly, a National Health Service-funded study is assessing AI's ability to analyze CT scans to diagnose blood clots, hoping it can discern information from the CT images that doctors might not see.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from